Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Large Decrease in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant decline in short interest in May. As of May 29th, there was short interest totaling 3,275 shares, a decline of 77.2% from the May 14th total of 14,337 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 21,621 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BRNS. Baird Financial Group Inc. increased its position in shares of Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after buying an additional 100,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after acquiring an additional 76,800 shares during the last quarter. Finally, Rangeley Capital LLC grew its stake in Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares during the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Trading Down 7.3%

Shares of NASDAQ:BRNS traded down $0.05 on Friday, reaching $0.67. 55,124 shares of the company were exchanged, compared to its average volume of 57,702. Barinthus Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $2.92. The firm has a market cap of $27.41 million, a price-to-earnings ratio of -0.52 and a beta of -0.40. The company has a 50-day moving average of $0.65 and a 200-day moving average of $0.67.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.